Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 12, 2026
Lumentum (LITE) Clears $1 Billion Revenue Milestone With Strong AI-Driven Beat

Lumentum (LITE) Clears $1 Billion Revenue Milestone With Strong AI-Driven Beat

Key Takeaways

  • Revenue surpassed $1 billion for the first time, reaching $1.01 billion and beating consensus estimates of $984.57 million by a comfortable margin.
  • Adjusted earnings per share (EPS) came in at $3.23, exceeding the analyst consensus of $2.95 by $0.28 and more than tripling the $0.88 reported in the same quarter last year.
  • Non-GAAP gross margin climbed to 50.4%, up 1,260 basis points year-over-year, driven by higher factory utilization, favorable product mix, and improved pricing.
  • Fiscal Q1 2027 guidance significantly outpaced expectations, with revenue projected between $1.225 billion and $1.275 billion versus a $1.16 billion consensus.
  • GAAP results included a one-time $7.8 billion non-cash charge tied to convertible debt equitization, resulting in a GAAP net loss of $7.2 billion for the quarter.
  • After-hours reaction was muted, with shares rising roughly 1.4%, suggesting the beat was substantially priced in following a 122% year-to-date rally.

Earnings Context and Why It Matters

Lumentum's fiscal fourth-quarter results, reported after the market close on August 11, 2026, represent a defining moment for the optical and photonic technologies leader. The company has become a direct beneficiary of the artificial intelligence (AI) infrastructure buildout, as hyperscale cloud providers racing to deploy GPU clusters at scale require dense optical interconnects to move data efficiently. This quarter marked Lumentum's eighth consecutive period of year-over-year revenue growth and its third straight quarter of sequential growth above 20%. With revenue crossing the $1 billion threshold for the first time and margins expanding sharply, the results offer a clear read on the intensity and durability of AI-driven demand for optical components and systems. For investors, the print also serves as a critical test of whether Lumentum's elevated valuation—shares were trading at a forward price-to-earnings ratio (P/E) near 165 heading into the report—can be sustained by the underlying growth trajectory. I also checked comparable names using Tickeron’s AI Screener to see how the momentum stacked up across the sector.

Reported Results

Lumentum delivered fiscal fourth-quarter net revenue of $1.01 billion for the period ended June 27, 2026, representing 109% year-over-year growth from $480.7 million and a 24% sequential increase from the prior quarter's $808.4 million. The result came in above the Wall Street consensus estimate of approximately $984.57 million.

On a non-GAAP (adjusted) basis, which excludes certain one-time items, the company posted earnings of $3.23 per diluted share, beating the analyst consensus of $2.95 by $0.28 and more than tripling the $0.88 per share earned in the same period a year ago.

The components segment generated $649.4 million in revenue, up 103% year-over-year and 22% sequentially, while the systems segment contributed $356.9 million, rising 123% from a year earlier and 30% quarter-over-quarter. Non-GAAP gross margin expanded to 50.4% from 37.8% a year ago, and non-GAAP operating margin reached 36.6%, compared with 15.0% in the prior-year quarter.

On a GAAP basis, the company recorded a net loss of $7.2 billion, or $84.65 per diluted share, driven entirely by a one-time, non-cash $7.8 billion charge associated with the equitization of a portion of its convertible notes. This transaction reduced Lumentum's outstanding convertible debt by approximately $1.1 billion, or roughly 35% of the total. Excluding that charge, underlying profitability was robust. The company ended the quarter with $2.7 billion in cash, cash equivalents, and short-term investments.

For the full fiscal year 2026, Lumentum reported net revenue of $3.01 billion, nearly doubling the $1.6 billion recorded in fiscal 2025.

Market Reaction and Investor Sentiment

Lumentum shares closed the regular trading session on August 11 at $820.19, down from intraday levels earlier in the week, as pre-earnings positioning reflected cautious sentiment following a sharp 5.2% decline in the prior session. In after-hours trading following the release, the stock edged approximately 1.4% higher to around $832–$835, indicating that the sizable beat on both revenue and earnings was largely anticipated by the market. The subdued reaction is consistent with a stock that had already rallied 122% year-to-date and roughly 585% over the trailing twelve months. With elevated expectations embedded in the share price and a forward P/E that leaves minimal room for disappointment, investors appeared to treat the results as confirmation rather than a catalyst for re-rating. Notably, the company's guidance for fiscal Q1 2027—which came in well above consensus at both the revenue and EPS midpoints—provided the strongest positive signal, though broader macro uncertainty and stretched valuations tempered aggressive buying in the after-hours session.

Forward Outlook and Key Factors to Monitor

Lumentum enters fiscal 2027 with considerable momentum. Management's guidance for the fiscal first quarter calls for revenue between $1.225 billion and $1.275 billion—with a midpoint of $1.25 billion that comfortably exceeds the $1.16 billion consensus—and adjusted EPS of $4.05 to $4.35, compared with analyst expectations of $3.63. The company also guided for non-GAAP operating margin of 39.5% to 40.5%, signaling confidence that margin expansion has further room to run.

Several product-level dynamics will shape the quarters ahead. The company reported record 800G cloud transceiver shipments and began initial production shipments of 1.6T (1.6 terabit) modules, with adoption expected to intensify through calendar 2027. Optical circuit switch (OCS) revenue doubled sequentially, and management expects the fiscal first quarter of 2027 to be the first with OCS revenue above $100 million. On the components side, pump laser shipments remain effectively sold out despite capacity expansion, with management projecting a fourfold increase over the next several quarters.

Key factors for investors to monitor include the pace of 1.6T transceiver adoption among hyperscale customers, execution on OCS capacity scaling, the trajectory of gross margins as factory utilization evolves, and any signals of demand moderation from cloud customers. The company's progress on co-packaged optics (CPO) and near-packaged optics (NPO) roadmaps also represents a longer-term catalyst worth tracking. On the risk side, the stock's premium valuation leaves it sensitive to any deceleration in sequential growth rates or shifts in sentiment around AI infrastructure spending. From what I see, the durability of that growth will be the real test ahead.

AI-Powered Research in Practice

I often rely on Tickeron’s AI Screener when preparing for earnings season. It helps quickly surface stocks with similar technical setups and momentum characteristics, which can add useful context when evaluating names like Lumentum alongside peers in the optical and AI infrastructure space. The platform’s ability to combine fundamental metrics with pattern recognition has become a regular part of my workflow for identifying relative strength before and after these reports.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LITE

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


LITE's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for LITE turned positive on August 03, 2026. Looking at past instances where LITE's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on LITE as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

LITE moved above its 50-day moving average on August 11, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LITE advanced for three days, in of 319 cases, the price rose further within the following month. The odds of a continued upward trend are .

LITE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LITE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for LITE entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LITE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LITE's P/B Ratio (21.459) is slightly higher than the industry average of (6.995). LITE has a moderately high P/E Ratio (143.224) as compared to the industry average of (68.763). LITE's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.164). LITE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (27.548) is also within normal values, averaging (13.675).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Cisco Systems (NASDAQ:CSCO), Hewlett Packard Enterprise Company (NYSE:HPE), Lumentum Holdings (NASDAQ:LITE), Ciena Corp (NYSE:CIEN), Nokia Corp (NYSE:NOK), Ericsson (NASDAQ:ERIC).

Industry description

The Telecommunications Equipment industry produces voice and data communications equipment, which includes fiber optic delivery products, digital signal processors, high-speed voice, data and video delivery. Additionally, satellite systems, global positioning systems, wireless data systems, personal communications equipment, telephone handsets and payload equipment for satellites also fall into this category. Apple Inc., QUALCOMM Incorporated and Nokia are major global players in this segment.

Market Cap

The average market capitalization across the Telecommunications Equipment Industry is 21.89B. The market cap for tickers in the group ranges from 1.59K to 474.67B. CSCO holds the highest valuation in this group at 474.67B. The lowest valued company is ABILF at 1.59K.

High and low price notable news

The average weekly price growth across all stocks in the Telecommunications Equipment Industry was 1%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 31%. CLRO experienced the highest price growth at 58%, while INSG experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Telecommunications Equipment Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 53
Price Growth Rating: 49
SMR Rating: 74
Profit Risk Rating: 74
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
LITE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of optical and photonic products

Industry TelecommunicationsEquipment

Profile
Details
Industry
Telecommunications Equipment
Address
1001 Ridder Park Drive
Phone
+1 408 546-5483
Employees
10562
Web
https://www.lumentum.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.